Literature DB >> 16710476

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Pal Kaposi-Novak1, Ju-Seog Lee, Luis Gòmez-Quiroz, Cédric Coulouarn, Valentina M Factor, Snorri S Thorgeirsson.   

Abstract

Identification of specific gene expression signatures characteristic of oncogenic pathways is an important step toward molecular classification of human malignancies. Aberrant activation of the Met signaling pathway is frequently associated with tumor progression and metastasis. In this study, we defined the Met-dependent gene expression signature using global gene expression profiling of WT and Met-deficient primary mouse hepatocytes. Newly identified transcriptional targets of the Met pathway included genes involved in the regulation of oxidative stress responses as well as cell motility, cytoskeletal organization, and angiogenesis. To assess the importance of a Met-regulated gene expression signature, a comparative functional genomic approach was applied to 242 human hepatocellular carcinomas (HCCs) and 7 metastatic liver lesions. Cluster analysis revealed that a subset of human HCCs and all liver metastases shared the Met-induced expression signature. Furthermore, the presence of the Met signature showed significant correlation with increased vascular invasion rate and microvessel density as well as with decreased mean survival time of HCC patients. We conclude that the genetically defined gene expression signatures in combination with comparative functional genomics constitute an attractive paradigm for defining both the function of oncogenic pathways and the clinically relevant subgroups of human cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710476      PMCID: PMC1462944          DOI: 10.1172/JCI27236

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

Review 1.  Cellular motility driven by assembly and disassembly of actin filaments.

Authors:  Thomas D Pollard; Gary G Borisy
Journal:  Cell       Date:  2003-02-21       Impact factor: 41.582

Review 2.  Integrative analysis of the cancer transcriptome.

Authors:  Daniel R Rhodes; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2005-06       Impact factor: 38.330

Review 3.  From signatures to models: understanding cancer using microarrays.

Authors:  Eran Segal; Nir Friedman; Naftali Kaminski; Aviv Regev; Daphne Koller
Journal:  Nat Genet       Date:  2005-06       Impact factor: 38.330

4.  Genotype-phenotype relationships in hepatocellular tumors from mice and man.

Authors:  Sabine Stahl; Carina Ittrich; Philip Marx-Stoelting; Christoph Köhle; Ozge Altug-Teber; Olaf Riess; Michael Bonin; Jürgen Jobst; Stephan Kaiser; Albrecht Buchmann; Michael Schwarz
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

5.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

Authors:  Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson
Journal:  Nat Med       Date:  2006-03-12       Impact factor: 53.440

Review 6.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

Review 7.  Cancer therapy: can the challenge be MET?

Authors:  Simona Corso; Paolo M Comoglio; Silvia Giordano
Journal:  Trends Mol Med       Date:  2005-06       Impact factor: 11.951

Review 8.  Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

9.  Scatter factor/hepatocyte growth factor is essential for liver development.

Authors:  C Schmidt; F Bladt; S Goedecke; V Brinkmann; W Zschiesche; M Sharpe; E Gherardi; C Birchmeier
Journal:  Nature       Date:  1995-02-23       Impact factor: 49.962

10.  The semaphorin 4D receptor controls invasive growth by coupling with Met.

Authors:  Silvia Giordano; Simona Corso; Paolo Conrotto; Stefania Artigiani; Giorgio Gilestro; Davide Barberis; Luca Tamagnone; Paolo M Comoglio
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

View more
  159 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Authors:  Luis E Gomez-Quiroz; Daekwan Seo; Yun-Han Lee; Mitsuteru Kitade; Timo Gaiser; Matthew Gillen; Seung-Bum Lee; Ma Concepcion Gutierrez-Ruiz; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson; Jens U Marquardt
Journal:  Toxicology       Date:  2016-07-06       Impact factor: 4.221

Review 3.  Emerging signaling pathways in hepatocellular carcinoma.

Authors:  Agrin Moeini; Helena Cornellà; Augusto Villanueva
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 4.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

5.  Gene expression profiling of HGF/Met activation in neonatal mouse heart.

Authors:  Stefano Gatti; Christian Leo; Simona Gallo; Valentina Sala; Enrico Bucci; Massimo Natale; Daniela Cantarella; Enzo Medico; Tiziana Crepaldi
Journal:  Transgenic Res       Date:  2012-12-06       Impact factor: 2.788

6.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Authors:  Mohd W Nasser; Jharna Datta; Gerard Nuovo; Huban Kutay; Tasneem Motiwala; Sarmila Majumder; Bo Wang; Saul Suster; Samson T Jacob; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

Review 7.  Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Authors:  Augusto Villanueva; Beatriz Minguez; Alejandro Forner; Maria Reig; Josep M Llovet
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro.

Authors:  Gaelle del Castillo; Valentina M Factor; Margarita Fernández; Alberto Alvarez-Barrientos; Isabel Fabregat; Snorri S Thorgeirsson; Aránzazu Sánchez
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

9.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.

Authors:  Liem M Phan; Enrique Fuentes-Mattei; Weixin Wu; Guermarie Velazquez-Torres; Kanishka Sircar; Christopher G Wood; Tao Hai; Camilo Jimenez; Gilbert J Cote; Levent Ozsari; Marie-Claude Hofmann; Siyuan Zheng; Roeland Verhaak; Lance Pagliaro; Maria Angelica Cortez; Mong-Hong Lee; Sai-Ching J Yeung; Mouhammed Amir Habra
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

10.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.